We performed mouse-specific qPCR analysis using the tumour tissues produced by Y-MESO-14 cells, and found that the expressions of both stromal CXCR4 and CCR7 were increased by bevacizumab treatment, and the expression of CCR7 was significantly lower in the tumour tissue compared with CXCR4 expression, (Supplementary Fig. 8), suggesting that CXCR4-positive population plays a role in bevacizumab resistance. Here, CCR7 is linked to neoplasm.